Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00181922
Status:
COMPLETED
Last Update Posted:
2013-10-22
First Post:
2005-09-13
Brief Title:
Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to compare the safety and effectiveness of Ziprasidone in the treatment of mania in children and adolescents with Bipolar disorder over 8 weeks This is an exploratory open-label study which seeks to determine if there is evidence for efficacy The results of this study will be used to generate hypotheses for a larger study
Detailed Description:
Initial clinical evidence suggests that atypical neuroleptics may play a unique therapeutic role in the management of symptoms in youth with bipolar disorder Ziprasidone is classed as an atypical neuroleptic because of its unique pharmacological profile that includes both D2 and 5HT2 antagonistic effects This combined dopaminergic and serotonergic activity seems to be associated not only with antipsychotic effects but also with mood stabilizing mood elevating and anti-aggressive effects as well as a lower risk for extrapyramidal symptoms and tardive dyskinesia
Ziprasidone in particular has been found to have a higher 5HT2A to D2 receptor affinity ratio which suggests that the likelihood of extrapyramidal symptoms and hyperprolactinemia may be further decreased This makes it an ideal candidate to treat mania in children but although it is used in clinical practice adequate data has not been collected on its safety and effectiveness This study included 1 an 8-week acute period during which participants were observed during weekly visits and up to a 10-month extension period during which participants saw a study clinician on a monthly basis to document the response rate 2 assessment of the impact of Ziprasidone on functional capacities quality of life psychosocial function and cognition 3 careful assessment of safety and tolerability
Ziprasidone in particular has been found to have a higher 5HT2A to D2 receptor affinity ratio which suggests that the likelihood of extrapyramidal symptoms and hyperprolactinemia may be further decreased This makes it an ideal candidate to treat mania in children but although it is used in clinical practice adequate data has not been collected on its safety and effectiveness This study included 1 an 8-week acute period during which participants were observed during weekly visits and up to a 10-month extension period during which participants saw a study clinician on a monthly basis to document the response rate 2 assessment of the impact of Ziprasidone on functional capacities quality of life psychosocial function and cognition 3 careful assessment of safety and tolerability
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None